الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 104 |  |  |
| | | from | 104 | | |
Abstract
Cataract surgery is one of the most common surgical procedures performed in the world. Although the complications of this surgery are relatively rare, endophthalmitis is a serious and potentially vision-threatening complication. Studies report an incidence rate after cataract surgery from 0.03% to 0.50%.
Moxifloxacin is a fourth-generation fluoroquinolone antibacterial agent that is active against many gram-positive, gram-negative, atypical, and anaerobic ocular pathogens. Considering the possible complications with vancomycin and cefuroxime, moxifloxacin seems to be the better choice of antibiotic for endophthalmitis prophylaxis because of its broad-spectrum coverage, mode of action and exhibits concentrationdependent efficacy. However, there is little prospective data on its safety.
Although applying drugs directly into the anterior chamber is effective in achieving high local concentration, one must take into account that this might injure the vulnerable human corneal endothelial cells (HCECs). Therefore, concentration ranges that are both nontoxic and effective must be defined.
The study is aimed to assess effect of intracameral injection of moxifloxacin on corneal endothelium after phacoemaulsification surgery.
This study is a Quasi-experimental study that was carried out at the Ophthalmology Outpatient clinic of Suez Canal Univeristy Hospital.
42 cases (42 eyes) were included in this study divided into two groups 21 eyes in each group. Study group (group A) were moxifloxacin will be injected intracamerally at the end of phacoemulsification surgery